The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ:BIIB) and its Alzheimer's med, Aduhelm (aducanumab).
- According to the Company's annual filing, the FTC has made a civil investigative demand in pursuit of documents related to Aduhelm's marketing and approval, plus healthcare sites, the Company said.
- Also See: After Much Criticism, Biogen Slashes Aduhelm Price In Half.
- The SEC, meanwhile, has launched a separate inquiry that also seeks marketing and approval information on the beleaguered anti-amyloid antibody.
- The lawmakers have also asked the FDA to produce additional data and documentation supporting its accelerated approval for the drug.
- Aduhelm's rocky rollout has translated into poor sales, too. The drug made just $1 million for the fourth quarter and $3 million for 2021.
- Price Action: BIIB shares are trading 0.91% higher at $222.17 during the market session on the last check Friday.
